226 related articles for article (PubMed ID: 32054358)
21. Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma.
Wang JW; Qian Y; Wu CS; Zhao NH; Fang Y; Yuan XD; Gao S; Fan YC; Wang K
Int J Med Sci; 2020; 17(18):3190-3199. PubMed ID: 33173438
[No Abstract] [Full Text] [Related]
22. Dysregulation of serum microRNA-574-3p and its clinical significance in hepatocellular carcinoma.
Shen X; Xue Y; Cong H; Wang X; Ju S
Ann Clin Biochem; 2018 Jul; 55(4):478-484. PubMed ID: 29065698
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
24. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma.
Yao M; Zhao J; Lu F
Oncotarget; 2016 Jan; 7(4):3702-8. PubMed ID: 26784252
[TBL] [Abstract][Full Text] [Related]
25. Serum des-gamma-carboxyprothrombin concentration determined by the avidin-biotin complex method in small hepatocellular carcinomas.
Saitoh S; Ikeda K; Koida I; Tsubota A; Arase Y; Chayama K; Kumada H
Cancer; 1994 Dec; 74(11):2918-23. PubMed ID: 7525036
[TBL] [Abstract][Full Text] [Related]
26. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
27. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
Li GJ; Chen QY; Harrison TJ; Wang XY; Hu LP; Yang QL; Li KW; Fang ZL
Cancer Biomark; 2017; 18(3):241-248. PubMed ID: 28085009
[TBL] [Abstract][Full Text] [Related]
28. Some patients with HCC haven't abnornormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels.
Bertino G; Ardiri AM; Santonocito MM; Boemi PM
Panminerva Med; 2009 Jun; 51(2):133-4. PubMed ID: 19776714
[No Abstract] [Full Text] [Related]
29. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
30. Inclusive Quantification Assay of Serum Des-γ-Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry.
Lee J; Lim YS; Lee JH; Gwak GY; Do M; Yeo I; Shin D; Han D; Park T; Kim Y
Hepatol Commun; 2021 Oct; 5(10):1767-1783. PubMed ID: 34558815
[TBL] [Abstract][Full Text] [Related]
31. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
[TBL] [Abstract][Full Text] [Related]
32. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
Yang Y; Fan YC; Gao S; Dou CY; Zhang JJ; Sun FK; Wang K
Tohoku J Exp Med; 2014 Mar; 232(3):187-94. PubMed ID: 24646840
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of serum AFP and DCP levels in the diagnosis of early-stage HBV-related HCC under different backgrounds.
Song T; Wang L; Xin R; Zhang L; Tian Y
J Int Med Res; 2020 Oct; 48(10):300060520969087. PubMed ID: 33135527
[TBL] [Abstract][Full Text] [Related]
34. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.
Ikoma J; Kaito M; Ishihara T; Nakagawa N; Kamei A; Fujita N; Iwasa M; Tamaki S; Watanabe S; Adachi Y
Hepatogastroenterology; 2002; 49(43):235-8. PubMed ID: 11941963
[TBL] [Abstract][Full Text] [Related]
35. [Symptoms of hepatocellular carcinoma. Laboratory tests used for its diagnosis and screening].
Gervain J
Orv Hetil; 2010 Aug; 151(35):1415-7. PubMed ID: 20719715
[TBL] [Abstract][Full Text] [Related]
36. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
37. 4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients.
Ren Y; Yang L; Li M; Wang J; Yan H; Ma N; Liu W; Wang L; Gao X; Gao P; Li T; Liu D
Sci Rep; 2021 Aug; 11(1):16982. PubMed ID: 34417517
[TBL] [Abstract][Full Text] [Related]
38. Des-gamma-carboxyprothrombin in hepatocellular carcinoma after vitamin K1 injection.
Buffet C; Bismuth E; Hagege H; Etienne JP
Dig Dis Sci; 1989 Jun; 34(6):963-4. PubMed ID: 2470560
[No Abstract] [Full Text] [Related]
39. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
[TBL] [Abstract][Full Text] [Related]
40. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A
Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
